ATRX - Adhera Therapeutics signs letter of intent to acquire cancer therapy
- Adhera Therapeutics ( OTCQB:ATRX ) said on Tuesday the company had entered a heads of terms agreement with Bio Innovation Group to acquire Paclitaxel Gallium Transferrin, a novel protein complex for targeted treatment of advanced cancers.
- Paclitaxel is a drug approved by the U.S. FDA in two variations, solvent-based paclitaxel and protein-based paclitaxel.
- Gallium nitrate is FDA-approved for hypercalcemia of malignancy, a common finding in patients with advanced stage cancer.
- Pre-clinical research suggests that switching the protein component to transferrin could have potential advantages over albumin for developing a new targeted therapy.
For further details see:
Adhera Therapeutics signs letter of intent to acquire cancer therapy